Reviews and feature articleNatural killer cell deficiency
Section snippets
NKD definition
To be considered an NKD, the impact upon NK cells need represent the major immunologic abnormality in the patient. Although many diseases, drugs, infections, and physiologic states can affect NK cell numbers, function, or both, the NKD diagnosis is reserved for abnormalities that are fixed over time and not secondary in nature. Specifically, NKD should be inherent and hardwired. In several cases a genetic mechanism responsible for NKD has been identified. It is also anticipated that the
CNKD
CNKD is characterized by the absence of both NK cells and their functions among peripheral blood lymphocytes. The single most well known case is that published in 1989 in the New England Journal of Medicine of an adolescent girl with multiple severe or disseminated herpesvirus infections, including varicella pneumonia, disseminated cytomegalovirus (CMV), and herpes simplex virus (HSV).22 She was stably deficient in NK cell cytotoxic activity, as measured by using K562 killing assays, and lacked
FNKD
FNKD describes patients with normal numbers of NK cells present in peripheral blood but ones that are functionally disabled in the face of otherwise effective immunity.46, 47, 48, 49, 50, 51 An example of a well-known PID that results in absent NK cell function (cytotoxicity) would be perforin deficiency.52 However, perforin deficiency is not considered an FNKD because it also abrogates the lytic function of CTLs. Thus the FNKD label is reserved for an effect on NK cells in relative isolation.
Known PIDs associated with an NK cell abnormality
Although CNKD and FNKD represent a specific subset of PIDs, there are at least 46 known genetically defined PIDs that include an effect on NK cell numbers, function, or both. They can be divided into diseases that (1) impair NK cell development or survival, (2) impair the mechanics of cytotoxicity, (3) impair signaling for cytotoxicity, and (4) impair some other mechanism. They are listed in Table III,52, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80
Treatment of NKDs
A variety of treatments are reported as having been applied to patients with CNKD and FNKD. That said, there has never been an organized clinical trial of any therapy in these patients. Most therapeutic approaches have focused on the susceptibility to herpesviruses and the application of prophylactic antiviral drugs. Anecdotal cases have described perceived success, with the most common being the use of acyclovir, ganciclovir, and related agents.22, 27, 47, 50 Breakthrough infections might
Conclusion
A growing number of patients have been recognized who have immunodeficiency that affects NK cells as the majority immune defect. A larger number of broader PIDs also include an NK cell abnormality, which has been mechanistically informative and potentially clinically useful. However, detailed clinical and phenotypic evaluation of patients with NKD has allowed paradigms to emerge, which include susceptibility to herpesviruses and HPV, as well as patients who lack NK cells (CNKD) or their
References (100)
- et al.
Natural killer cells: walking three paths down memory lane
Trends Immunol
(2013) Human natural killer cells
Blood
(2008)- et al.
A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells
Immunity
(2005) - et al.
Viral evasion of T cell immunity: ancient mechanisms offering new applications
Curr Opin Immunol
(2011) - et al.
Modulation of natural killer cell activity by viruses
Curr Opin Microbiol
(2010) - et al.
Practice parameter for the diagnosis and management of primary immunodeficiency
Ann Allergy Asthma Immunol
(2005) Human natural killer cell deficiencies and susceptibility to infection
Microbes Infect
(2002)- et al.
A patient with simultaneous absence of “classical” natural killer cells (CD3-, CD16+, and NKH1+) and expansion of CD3+, CD4-, CD8-, NKH1+ subset
J Allergy Clin Immunol
(1990) - et al.
A novel primary immunodeficiency with specific natural-killer cell deficiency maps to the centromeric region of chromosome 8
Am J Hum Genet
(2006) - et al.
Fatal varicella associated with selective natural killer cell deficiency
J Pediatr
(2005)
Classical natural killer cell deficiency (CNKD): a new case
Clin Immunol
Natural killer cell deficiencies and severe varicella infection
J Pediatr
Strong αβ and γδ TCR response in a patient with disseminated mycobacterium avium infection and lack of NK cells and monocytopenia
Immunol Lett
Bilateral adrenal EBV-associated smooth muscle tumors in a child with a natural killer cell deficiency
Blood
Defective expression of the interleukin-2/interleukin-15 receptor beta subunit leads to a natural killer cell-deficient form of severe combined immunodeficiency
Blood
Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset
Blood
Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia
Blood
Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome
Blood
Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency
Blood
Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency
Blood
A non-x-linked syndrome with susceptibility to severe Epstein-Barr virus infections
J Pediatr
Identification of an unusual Fcg receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections
Blood
Recalcitrant warts, associated with natural killer cell dysfunction, treated with systemic IFN-alpha
J Allergy Clin Immunol
The relationship of depression and stressors to immunological assays: a meta-analytic review
Brain Behav Immun
NK-cell activity in immunotoxicity drug evaluation
Toxicology
Rapid activation receptor- or IL-2-induced lytic granule convergence in human natural killer cells requires Src, but not downstream signaling
Blood
Defective actin accumulation impairs human natural killer cell function in patients with dedicator of cytokinesis 8 deficiency
J Allergy Clin Immunol
Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants
J Pediatr
Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation
Blood
Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3)
Cell
Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients
Blood
Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome
Mol Genet Metab
Different NK cell-activating receptors preferentially recruit Rab27a or Munc13-4 to perforin-containing granules for cytotoxicity
Blood
Exome sequencing reveals a pallidin mutation in a Hermansky-Pudlak-like primary immunodeficiency syndrome
Blood
A family with Papillon-Lefevre syndrome reveals a requirement for cathepsin C in granzyme B activation and NK cell cytolytic activity
Blood
Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity
Blood
Loss of kindlin-3 alters the threshold for NK cell activation in human leukocyte adhesion deficiency-III
Blood
XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease
Blood
Synergistic activation of phospholipases Cgamma and Cbeta: a novel mechanism for PI3K-independent enhancement of FcepsilonRI-induced mast cell mediator release
Cell Signal
Severe impairment of IFN-gamma and IFN-alpha responses in cells of a patient with a novel STAT1 splicing mutation
Blood
Tolerance of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient patient (bare lymphocyte syndrome type I)
Hum Immunol
The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients
Blood
Comel-Netherton syndrome defined as primary immunodeficiency
J Allergy Clin Immunol
A role for interleukin-12/23 in the maturation of human natural killer and CD56+ T cells in vivo
Blood
Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity
Clin Immunol
Functions of natural killer cells
Nat Immunol
Innate lymphoid cells—a proposal for uniform nomenclature
Nat Rev Immunol
CD56bright natural killer (NK) cells: an important NK cell subset
Immunology
Up on the tightrope: natural killer cell activation and inhibition
Nat Immunol
Control of human viral infections by natural killer cells
Annu Rev Immunol
Cited by (393)
Developing CAR-immune cell therapy against SARS-CoV-2: Current status, challenges and prospects
2024, Biochemical PharmacologyComprehensive analysis of ASB3 as a prognostic biomarker in hepatocellular carcinoma
2024, Translational OncologyNK cells vs. obesity: A tale of dysfunction & redemption
2023, Clinical ImmunologyCutaneous Findings in Inborn Errors of Immunity: An Immunologist's Perspective
2023, Journal of Allergy and Clinical Immunology: In PracticeAntitumor mechanism of cannabidiol hidden behind cancer hallmarks
2023, Biochimica et Biophysica Acta - Reviews on Cancer
Series editors: Donald Y. M. Leung, MD, PhD, and Dennis K. Ledford, MD
Supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases grant R01067946 and the Jeffrey Modell Foundation.